Information de reference pour ce titreAccession Number: | 00002953-200411000-00016.
|
Author: | Shafazand, Shirin MD, MS, FCCP; Goldstein, Mary K. MD, MSc; Doyle, Ramona L. MD, FCCP; Hlatky, Mark A. MD; Gould, Michael K. MD, MS, FCCP
|
Title: | |
Source: | Chest. 126(5):1452-1459, November 2004.
|
Abstract: | Study objectives: Patients with pulmonary arterial hypertension (PAH) often present with dyspnea and severe functional limitations, but their health-related quality of life (HRQOL) has not been studied extensively. This study describes HRQOL in a cohort of patients with PAH.
Design: Cross-sectional study.
Setting: A tertiary care, university hospital-based, pulmonary hypertension (PH) clinic.
Participants: We studied HRQOL in 53 patients with PAH (mean age, 47 years; median duration of disease, 559 days). Eighty-three percent were women, 53% received epoprostenol, and 72% reported moderate-to-severe functional limitations with a New York Heart Association class 3 or 4 at enrollment.
Measurements and results: We examined HRQOL by administering the Nottingham Health Profile, Congestive Heart Failure Questionnaire, and Hospital Anxiety and Depression Scale. We used the Visual Analog Scale and standard gamble (SG) techniques to measure preferences for current health (utilities). Compared with population norms, participants reported moderate-to-severe impairment in multiple domains of HRQOL, including physical mobility, emotional reaction, pain, energy, sleep, and social isolation. Mean SG utilities were 0.71, suggesting that, on average, participants were willing to accept a 29% risk of death in order to be cured of PH.
Conclusions: PAH is a devastating condition that affects predominately young women in the prime of their life. Understanding HRQOL and preferences are important in the care and management of these patients. Compared with population norms, patients with PAH have substantial functional and emotional limitations that adversely affect their HRQOL.
Copyright (C) 2004 by the American College of Chest Physicians
|
Author Keywords: | attitude to health; epoprostenol; health status; hypertension; pulmonary; quality of life.
|
References: | 1 Gaine S. Pulmonary hypertension. JAMA 2000; 284:3160-3168
2 D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
3 Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
4 Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
5 McLaughlin VV. Medical management of primary pulmonary hypertension. Expert Opin Pharmacother 2002; 3:159-165
6 Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension: conventional therapies. Clin Chest Med 2001; 22:517-527
7 Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995; 273:59-65
8 Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835-840
9 O'Brien BJ, Banner NR, Gibson S, et al. The Nottingham Health Profile as a measure of quality of life following combined heart and lung transplantation. J Epidemiol Community Health 1988; 42:232-234
10 Hunt SM, McKenna SP, McEwen J, et al. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980; 34:281-286
11 Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993; 22:185A-191A
12 Guyatt G. Measurement of health-related quality of life in chronic airflow limitation. Monaldi Arch Chest Dis 1993; 48:554-557
13 Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 2002; 52:69-77
14 Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 2000; 48:579-584
15 Herrmann C. International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 1997; 42:17-41
16 Hunt SM, McEwen J. The development of a subjective health indicator. Sociol Health Illn 1980; 2:231-246
17 Guyatt GH, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4:101-107
18 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370
19 Sumner W, Nease R, Littenberg B. U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care 1991:701-705
20 Stalmeier PF, Goldstein MK, Holmes AM, et al. What should be reported in a methods section on utility assessment? Med Decis Making 2001; 21:200-207
21 Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5:1-30
22 Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. Prim Care 1995; 22:271-280
23 Naglie G, Krahn MD, Naimark D, et al. Primer on medical decision analysis: part 3; estimating probabilities and utilities. Med Decis Making 1997; 17:136-141
24 Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 1994; 29:207-224
25 Goldstein M, Tsevat J. Symptom research: methods and opportunities; assessing desirability of outcomes states for medical decision making and cost effectiveness analysis. Available at: http://symptomresearch.nih.gov/i...- ouverture dans une nouvelle fenêtre. Accessed March 15, 2004
26 Hunt SM, McEwen J, McKenna SP. Perceived health: age and sex comparisons in a community. J Epidemiol Commun Health 1984; 38:156-160
27 Congleton J, Hodson ME, Duncan-Skingle F. Quality of life in adults with cystic fibrosis. Thorax 1996; 51:936-940
28 Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15:221-229
29 Bennett SJ, Oldridge NB, Eckert GJ, et al. Comparison of quality of life measures in heart failure. Nurs Res 2003; 52:207-216
30 Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 1981; 211:453-458
31 Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001; 21:288-294
32 Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447
|
Language: | English.
|
Document Type: | Clinical Investigations: PULMONARY VASCULAR DISEASE.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0012-3692
|
NLM Journal Code: | 0231335, d1c
|
Annotation(s) | |
|
|